Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biomarin
Biomarin
3 Orphan Drugmakers to Watch
Motley Fool
Wed, 10/23/13 - 08:43 am
orphan drugs
Biomarin
GSK
Vimizim
Tafinlar
Mekinist
Myozyme
Cerazyme
Sanofi
Catalyst Pharmaceuticals And Their Business Plan
Seeking Alpha
Mon, 10/21/13 - 11:51 am
Catalyst Pharmaceutical Partners
Biomarin
Biogen Idec
Firdapse
Lambert-Eaton myasthenic syndrome
Five Data Presentations on BioMarin's BMN 673 PARP Inhibitor at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Yahoo/Globe Newswire
Sun, 10/20/13 - 02:29 pm
Biomarin
BMN 673
solid tumors
Top Biotechs Set to Win in the War on Cancer
Yahoo/Wall St 24-7
Thu, 10/3/13 - 11:57 am
biotech
Biomarin
Immunogen
Ariad Pharmaceuticals
Amgen
Celgene
Gilead Sciences
BioMarin Provides Updated Phase 1/2 Data on BMN 673 in Breast Cancer at the European Cancer Congress 2013
Yahoo/GlobeNewsWire
Sun, 09/29/13 - 01:33 pm
BMN 673
breast cancer
Biomarin
BioMarin doses first patient in Phase 1/2 trial with BMN 190
Yahoo/Fly on the Wall
Mon, 09/23/13 - 10:48 am
Biomarin
BMN-190
Batten disease
BioMarin's Buyout False Start Leads Biotech's Record Surge
Motley Fool
Sun, 09/22/13 - 11:32 am
Biomarin
Roche
Roche CEO Says Drugmaker Isn’t Seeking Financing for Deal
Bloomberg
Fri, 09/20/13 - 09:53 am
Roche
Pharma CEOs
Severin Schwan
M&A
Biomarin
5 Things You Need to Know From BioMarin's R&D Day
Motley Fool
Thu, 09/19/13 - 03:09 am
R&D
Biomarin
Vimizim
BMN-701
BMN-111
BMN-673
Are Biotech M&A Premiums Already Built In? Valuations Do Matter
Seeking Alpha
Tue, 09/3/13 - 04:19 pm
biotech
M&A
ONYX Pharmaceuticals
Alexion
Biomarin
Incyte
Medivation
Pharmacyclics
Regeneron
Seattle Genetics
3 PDUFA Dates That Will Kick Off 2014
Motley Fool
Tue, 08/27/13 - 05:34 pm
FDA
diabetes
Forixga
Bristol-Myers Squibb
AstraZeneca
Biomarin
Vimizim
Amylin
metreleptin
Tiny Catalyst soars after rare disease drug scores 'breakthrough' at FDA
Fierce Biotech
Tue, 08/27/13 - 11:01 am
Catalyst Pharmaceutical Partners
Firdapse
Biomarin
FDA
breakthrough therapies
Lambert-Eaton myasthenic syndrome
What Does The FDA's Breakthrough Designation Mean For Investors?
Seeking Alpha
Mon, 08/26/13 - 01:28 pm
FDA
breakthrough therapies
AbbVie
Alexion
Ariad Pharmaceuticals
Biomarin
Bristol-Myers Squibb
SynaGeva BioPharma
GSK
JNJ
Merck
Novartis
Pharmacyclics
Pfizer
Vertex Pharmaceuticals
daratumumab
ibrutinib
Kalydeco
lambrolizumab
palbociclib
LDK378
SD-101
obinutuzumab
serelaxin
asfotase alfa
bimagrumab
drisapersen
sebelipase alfa
Is There Any Substance To The Buyout Rumors Surrounding BioMarin And Catalyst?
Seeking Alpha
Mon, 08/26/13 - 09:46 am
M&A
Biomarin
Catalyst Pharmaceutical Partners
BioMarin Announces Oral Presentation of BMN 673 Most Recent Data on Breast and Ovarian Cancers at the European Cancer Congress 2013
Yahoo/GlobeNewsWire
Sat, 08/17/13 - 10:42 am
Biomarin
BMN 673
breast cancer
ovarian cancer
2 Biotech Stocks That Could Be on Novartis' Buyout Radar
Motley Fool
Thu, 08/15/13 - 11:48 am
Novartis
M&A
Biomarin
Incyte
Shire, Vertex, BioMarin among firms lobbying Congress to maintain orphan drug tax credit in proposed tax reform
FT.com
Mon, 07/29/13 - 01:39 pm
Shire
Vertex Pharmaceuticals
Biomarin
orphan drugs
Orphan Drug Tax Credit
BioMarin Provides BMN 673 Program Update
Virtual Strategy
Sat, 07/27/13 - 11:25 am
Biomarin
BMN 673
breast cancer
5 Drugmakers With a Lot on the Line Next Week
Motley Fool
Sun, 07/21/13 - 11:37 am
Eli Lilly
InterMune
Gilead Sciences
Alexion
Biomarin
Exploding Pipeline Makes BioMarin Attractive Takeover Target
Motley Fool
Thu, 07/11/13 - 10:33 am
Biomarin
M&A
Pfizer
Sanofi
Pages
« first
‹ previous
…
8
9
10
11
12
13
14
15
16
…
next ›
last »